136P - Serum phosphorylated neurofilament heavy subunit as a predictive marker of chemotherapy-induced cognitive impairment: a preliminary result

Date 10 October 2016
Event ESMO 2016 Congress
Session Poster display
Topics Complications of Treatment
Translational Research
Presenter Kumiko Kida
Citation Annals of Oncology (2016) 27 (6): 15-42. 10.1093/annonc/mdw363
Authors K. Kida1, M. Sumitani2, T. Ogata3, R. Kotake1, A. Natori4, J. Hashimoto5, H. Yamauchi1, T. Yamauchi5
  • 1Breast Surgical Oncology, St. Luke's International Hospital, 1048560 - Tokyo/JP
  • 2Pain And Palliative Medicine, University of Tokyo, Tokyo/JP
  • 3Center For Sports Sciences And Health Promotion, National Rehabilitation Center for Persons with Disabilities, Tokyo/JP
  • 4Department Of Medical Oncology And Hematology, Princess Margaret Cancer Centre, Toronto/CA
  • 5Medical Oncology, St. Luke's International Hospital, 1048560 - Tokyo/JP

Abstract

Background

Chemotherapy-induced cognitive impairments (CICI) have been recognized as a clinically significant problem for cancer survivors, but its assessment method has not been established yet. We previously reported in a cross-sectional study that the serum phosphorylated neurofilament heavy subunit (pNF-H), a biomarker of axonal damage, is increased in breast cancer patients treated with chemotherapy. The aim of this study is to evaluate the association of serum pNF-H level with cognitive functions and brain volume changes after sequential chemotherapy.

Methods

Fifteen breast cancer patients who received neoadjuvant or adjuvant chemotherapy underwent cognitive functions tests [Controlled Oral Word Association (COWA), Trail Making Test (TMT), and Hopkins Verbal Learning Test-Revised (HVLT-R)], questionnaires reporting anxiety/depression, and brain MRI, at the baseline period (before chemotherapy) and at one month after finishing the course of chemotherapy (post-period). Serum pNF-H levels were measured at the baseline, every 3 weeks during chemotherapy and at the post-period (9 times in total). Brain MRI volumetry was determined by the BAAD® (Brain Anatomical Analysis using Dartel) software. The correlations between cognitive functions, brain volume, and pNF-H levels [cumulative pNF-H (cumulo-pNF-H), maximum pNF-H (max-pNF-H), pNF-H at 3 weeks after beginning chemotherapy (3wks-pNF-H)] were statistically analyzed.

Results

Patients' median age was 48 years (range 42-73). At baseline, only one patient demonstrated elevated pNF-H level, which was not associated with cognitive functions or brain volumetry. During the course of chemotherapy, pNF-H was elevated in 13 patients. Cumulo-pNF-H, max-pNF-H and 3wks-pNF-H were significantly correlated with cognitive dysfunction on TMT and COWA taken at the post-period. Furthermore, cumulo-pNF-H and max-pNF-H at the post-period were significantly correlated with brain atrophy index and white matter volume loss in some regions.

Conclusions

This preliminary study suggests that serum pNF-H levels of breast cancer patients undergoing chemotherapy can predict CICI and brain atrophy.

Clinical trial identification

Legal entity responsible for the study

N/A

Funding

Japan agency for medical research and development

Disclosure

All authors have declared no conflicts of interest.